Showing 119 results
Archivistische beschrijving![[Gi] Health Service Commissioning of TrikaftaKaftrio NHS England.pdf](/uploads/r/null/5/6/7/5679d95879085b5cf3c340b33165aac0aa4a93dc172e884f5cb5f21775c07feb/e1b1cfef-9479-4860-aedf-4cc23f19e733-_Gi__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_England_142.jpg)
[Gi] Health Service Commissioning of TrikaftaKaftrio NHS England.pdf
![[Giii] Health Service Commissioning of TrikaftaKaftrio Northern Ireland.pdf](/uploads/r/null/c/f/b/cfb1b31923f41e01a108288ec61634772d5a1dc918bb35888dda3f0ae8e33eaa/d0bfc5e3-cfe6-4be6-951d-d2286ffc7dad-_Giii__Health_Service_Commissioning_of_TrikaftaKaftrio_Northern_Ireland_142.jpg)
[Giii] Health Service Commissioning of TrikaftaKaftrio Northern Ireland.pdf
MED01-11
MED01-11
![[G] Pulmonx Zephyr valve.pdf](/uploads/r/null/f/9/0/f90bfe237acefc35119e7609151b96cd00628a943df50b358a252276e3eb074c/6053c1ce-af83-4ae2-b9c9-a1a7b23693f0-_G__Pulmonx_Zephyr_valve_142.jpg)
[G] Pulmonx Zephyr valve.pdf
![[H] UK Taskforce for Lung Health A National Five Year Plan for Lung Health (Recommendation 3B P57) 2019.pdf](/uploads/r/null/1/f/a/1fa4627b8103efd7ac7be53be778c82de2186adf3e28cb89c3dffa3a2161c30c/c14158fe-b62c-4619-b6e5-31e31735685d-_H__UK_Taskforce_for_Lung_Health_A_National_Five_Year_Plan_for_Lung_Health__Recommendation_3B_P57__2019_142.jpg)
[H] UK Taskforce for Lung Health A National Five Year Plan for Lung Health (Recommendation 3B P57) 2019.pdf
![[F] GAVI (2018). Vaccine Investment Strategy.pdf](/uploads/r/null/8/3/3/8331491baa9a3287f4bff22a325f1204ce725264cbd52ac9341070e7a2d0b358/9012e9cf-8765-4b44-b5bf-3ceb7a53e2ec-_F__GAVI__2018_._Vaccine_Investment_Strategy_142.jpg)
[F] GAVI (2018). Vaccine Investment Strategy.pdf
![[C] WHO Press Release 22nd September 2014 .pdf](/uploads/r/null/a/b/6/ab6ff6a0a7ad1a76fef10b9023a8f17160e4293fa920b94fd648ada16a5eb7b2/649e034e-9c59-4b93-906a-aac271c4eaaf-_C__WHO_Press_Release_22nd_September_2014___142.jpg)
[C] WHO Press Release 22nd September 2014 .pdf
![[G] Nutritional care of children and adults with Ebola virus disease in treatment centres Interim guideline WHO 2014.pdf](/uploads/r/null/9/1/1/911211c7938cec181640baf205aeb97e0607989c6ca716f98c4658349906acaa/7c74e69c-46f1-467e-b662-ddab76f18957-_G__Nutritional_care_of_children_and_adults_with_Ebola_virus_disease_in_treatment_centres_Interim_guideline_WHO_2014_142.jpg)
[G] Nutritional care of children and adults with Ebola virus disease in treatment centres Interim guideline WHO 2014.pdf
![[H] WHO SAGE Vaccine Committee Meeting April 2017. Ebola vaccine background document..pdf](/uploads/r/null/2/e/9/2e9ba0f3870a6b197e58c4d64317210f1d7e6341a335c052ff5aa617cd0660f2/a57d6e52-e42d-4c55-9085-80c029eeaf0e-_H__WHO_SAGE_Vaccine_Committee_Meeting_April_2017._Ebola_vaccine_background_document._142.jpg)
[H] WHO SAGE Vaccine Committee Meeting April 2017. Ebola vaccine background document..pdf
![[Aiv]WHO Global Tuberculosis Report 2018.pdf](/uploads/r/null/9/d/0/9d0e0eb62785075c49cf0366af81810aa2b6fa2fd034abbceab790a78365fde2/9048910d-9f55-46a8-88f8-d682427060a4-_Aiv_WHO_Global_Tuberculosis_Report_2018_142.jpg)
[Aiv]WHO Global Tuberculosis Report 2018.pdf
![[B] Letter to NHS Trusts.pdf](/uploads/r/null/f/8/f/f8f244a6212c08f0267fd0e7138339e6f93df4def01a5af885a62aaaf9f7e27a/7e20d7f4-7061-4736-a11e-be081db222d4-_B__Letter_to_NHS_Trusts_142.jpg)
[B] Letter to NHS Trusts.pdf
![[D] List of Approved coronavirus test providers.pdf](/uploads/r/null/c/2/c/c2cda6875638437cb68c2de936e457e366519403d519401cf882f8978885ee8d/7ca6b49b-ee18-4bf9-bf6a-39ed9edf3cf9-_D__List_of_Approved_coronavirus_test_providers_142.jpg)
[D] List of Approved coronavirus test providers.pdf
![[E] government news roll out of 2 new rapid coronavirus tests ahead of winter .pdf](/uploads/r/null/4/b/9/4b9efe17a198dd9745c6d70da3ba9a13b1f51dde03faefaed536c08584052300/3db5ecbb-9b37-42df-bca1-7aa9cd53cc11-_E__government_news_roll_out_of_2_new_rapid_coronavirus_tests_ahead_of_winter__142.jpg)
[E] government news roll out of 2 new rapid coronavirus tests ahead of winter .pdf
MED01-03
MED01-03
![[E] Updated surveillance guidance for people who have had polyps or previous cancer removed.pdf](/uploads/r/null/e/e/3/ee3a052f610b24e319819c3ddb1e80935745b18b3103a94762cf53da993abd36/3d481dd8-1892-4ec7-9dfe-ce3321d71153-_E__Updated_surveillance_guidance_for_people_who_have_had_polyps_or_previous_cancer_removed_142.jpg)
[E] Updated surveillance guidance for people who have had polyps or previous cancer removed.pdf
![[H] Adenoma_surveillance_second_edition withdrawn.pdf](/uploads/r/null/1/f/b/1fbf486beddc2c91806ee3f77e9fd136411bc34129488c81ae37ff0364a6c0c2/fe81758e-9633-4f5a-a1e2-f5376035fcac-_H__Adenoma_surveillance_second_edition_withdrawn_142.jpg)
[H] Adenoma_surveillance_second_edition withdrawn.pdf
![[Bii] Royal College of Obstetricians and Gynaecologists Green Top Guideline number 62 Green top Guideline No. 62 RCOG BSGE Joint Guideline.pdf](/uploads/r/null/7/6/b/76bdf691407d27c069b02c7316ef0866d0637ac773bf6fd55e907391d7c9e386/3151a4cf-70e4-4414-9cc0-45905a0b731e-_Bii__Royal_College_of_Obstetricians_and_Gynaecologists_Green_Top_Guideline_number_62_Green_top_Guideline_No._62_RCOG_BSGE_Joint_Guideline_142.jpg)
[Bii] Royal College of Obstetricians and Gynaecologists Green Top Guideline number 62 Green top Guideline No. 62 RCOG BSGE Joint Guideline.pdf
![[C] Royal College of Obstetricians and Gynaecologists Green Top Guideline number 34 for the management of Ovarian cysts in Postmenopausal women.pdf](/uploads/r/null/7/1/2/7124cb55e6d1865c6baca004aa2435ef2ec06249937b344838cb4aacba3c4ca8/32a8973e-c664-4173-b235-f407a51b803e-_C__Royal_College_of_Obstetricians_and_Gynaecologists_Green_Top_Guideline_number_34_for_the_management_of_Ovarian_cysts_in_Postmenopausal_women_142.jpg)
[C] Royal College of Obstetricians and Gynaecologists Green Top Guideline number 34 for the management of Ovarian cysts in Postmenopausal women.pdf
![[C] Volcano obtains FDA clearance of its instant wave-Free Ratio modality.pdf](/uploads/r/null/1/b/1/1b17355b3cc198592376885d4dc5e2a631fcb7ae54455d45d0b5572ff8b583c3/d4100c79-d841-4258-987d-ba2dc7613a63-_C__Volcano_obtains_FDA_clearance_of_its_instant_wave-Free_Ratio_modality_142.jpg)
[C] Volcano obtains FDA clearance of its instant wave-Free Ratio modality.pdf
![[C] The Value of Ripple Mapping .pdf](/uploads/r/null/0/1/a/01adc88139c7f4c46014587fb9d1fe1fbc9dbc38cdcdd2f100fd779b9dcb50b8/0dffd0bc-5d4f-466d-83c4-f0f337273d41-_C__The_Value_of_Ripple_Mapping__142.jpg)
[C] The Value of Ripple Mapping .pdf